drugset
drugset / Trial / NCT03853044

Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

NCT03853044 ↗

Phase 2 Unknown 23 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label phase 2study of Chidamide in combination with CHOP in the treatment of subjects with untreated angioimmunoblastic T cell lymphoma.

Timeline

Start
2018-12-29
Primary completion
2021-06-30
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 20 mg Oral
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Prednisone Other / unclassified 60 mg/m2 Oral
Background Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications

angioimmunoblastic T-cell lymphoma